Karin Kast1, Julia Häfner2,3,4, Evelin Schröck3,4,5,6, Arne Jahn3,4,5,6, Carmen Werner7, Cornelia Meisel2,3,4, Pauline Wimberger2,3,4. 1. Center of Familial Breast and Ovarian Cancer and Center of Integrated Oncology, University Hospital Cologne, Cologne, Germany. 2. Department of Gynecology and Obstetrics, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. 3. National Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, Germany. 4. German Cancer Consortium (DKTK) Dresden and German Cancer Research Center (DKFZ) Heidelberg, Heidelberg, Germany. 5. Institute for Clinical Genetics, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany. 6. Hereditary Cancer Syndrome Center Dresden, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany. 7. Regional Clinical Cancer Registry, TU Dresden, Dresden, Germany.
Abstract
Background: In clinical routine, not every patient who is offered genetic counselling and diagnostics in order to investigate a familial cancer risk predisposition opts for it. Little is known about acceptance of counselling and testing in newly diagnosed breast cancer cases in Germany. Methods: All primary breast cancer cases and patients with DCIS (ductal carcinoma in situ) treated at the University Hospital of Dresden between 2016 and 2019 were included. The number of tumor board recommendations for genetic counselling on the basis of the GC-HBOC risk criteria was recorded. Acceptance was analyzed by number of cases with counselling in the GC-HBOC-Center Dresden. Results: Of 996 primary breast cancer and DCIS cases, 262 (26.3%) were eligible for genetic counselling. Recommendation for genetic counselling was accepted by 64.1% (168/262). Of these 90.5% (152/168) opted for molecular genetic analysis. The acceptance rate for counselling increased between 2016 and 2019 from 58.3 to 72.6%. Altogether, 20.4% (31/152) patients were found to carry a pathogenic variant in the breast cancer genes BRCA1 or BRCA2. Conclusion: Acceptance of recommendation is increasing as clinical consequences augment. Optimization in providing information about hereditary cancer risk and in accessibility of counselling and testing is required to further improve acceptance of recommendation.
Background: In clinical routine, not every patient who is offered genetic counselling and diagnostics in order to investigate a familial cancer risk predisposition opts for it. Little is known about acceptance of counselling and testing in newly diagnosed breast cancer cases in Germany. Methods: All primary breast cancer cases and patients with DCIS (ductal carcinoma in situ) treated at the University Hospital of Dresden between 2016 and 2019 were included. The number of tumor board recommendations for genetic counselling on the basis of the GC-HBOC risk criteria was recorded. Acceptance was analyzed by number of cases with counselling in the GC-HBOC-Center Dresden. Results: Of 996 primary breast cancer and DCIS cases, 262 (26.3%) were eligible for genetic counselling. Recommendation for genetic counselling was accepted by 64.1% (168/262). Of these 90.5% (152/168) opted for molecular genetic analysis. The acceptance rate for counselling increased between 2016 and 2019 from 58.3 to 72.6%. Altogether, 20.4% (31/152) patients were found to carry a pathogenic variant in the breast cancer genes BRCA1 or BRCA2. Conclusion: Acceptance of recommendation is increasing as clinical consequences augment. Optimization in providing information about hereditary cancer risk and in accessibility of counselling and testing is required to further improve acceptance of recommendation.
Authors: Susan M Domchek; Tara M Friebel; Christian F Singer; D Gareth Evans; Henry T Lynch; Claudine Isaacs; Judy E Garber; Susan L Neuhausen; Ellen Matloff; Rosalind Eeles; Gabriella Pichert; Laura Van t'veer; Nadine Tung; Jeffrey N Weitzel; Fergus J Couch; Wendy S Rubinstein; Patricia A Ganz; Mary B Daly; Olufunmilayo I Olopade; Gail Tomlinson; Joellen Schildkraut; Joanne L Blum; Timothy R Rebbeck Journal: JAMA Date: 2010-09-01 Impact factor: 56.272
Authors: Hermela Shimelis; Holly LaDuca; Chunling Hu; Steven N Hart; Jie Na; Abigail Thomas; Margaret Akinhanmi; Raymond M Moore; Hiltrud Brauch; Angela Cox; Diana M Eccles; Amanda Ewart-Toland; Peter A Fasching; Florentia Fostira; Judy Garber; Andrew K Godwin; Irene Konstantopoulou; Heli Nevanlinna; Priyanka Sharma; Drakoulis Yannoukakos; Song Yao; Bing-Jian Feng; Brigette Tippin Davis; Jenna Lilyquist; Tina Pesaran; David E Goldgar; Eric C Polley; Jill S Dolinsky; Fergus J Couch Journal: J Natl Cancer Inst Date: 2018-08-01 Impact factor: 13.506
Authors: Jennifer L Caswell-Jin; Anjali D Zimmer; Will Stedden; Kerry E Kingham; Alicia Y Zhou; Allison W Kurian Journal: J Natl Cancer Inst Date: 2019-01-01 Impact factor: 13.506
Authors: Barbara Wappenschmidt; Jan Hauke; Ulrike Faust; Dieter Niederacher; Lisa Wiesmüller; Gunnar Schmidt; Evi Groß; Andrea Gehrig; Christian Sutter; Juliane Ramser; Andreas Rump; Norbert Arnold; Alfons Meindl Journal: Geburtshilfe Frauenheilkd Date: 2020-04-21 Impact factor: 2.915
Authors: Karoline B Kuchenbaecker; John L Hopper; Daniel R Barnes; Kelly-Anne Phillips; Thea M Mooij; Marie-José Roos-Blom; Sarah Jervis; Flora E van Leeuwen; Roger L Milne; Nadine Andrieu; David E Goldgar; Mary Beth Terry; Matti A Rookus; Douglas F Easton; Antonis C Antoniou; Lesley McGuffog; D Gareth Evans; Daniel Barrowdale; Debra Frost; Julian Adlard; Kai-Ren Ong; Louise Izatt; Marc Tischkowitz; Ros Eeles; Rosemarie Davidson; Shirley Hodgson; Steve Ellis; Catherine Nogues; Christine Lasset; Dominique Stoppa-Lyonnet; Jean-Pierre Fricker; Laurence Faivre; Pascaline Berthet; Maartje J Hooning; Lizet E van der Kolk; Carolien M Kets; Muriel A Adank; Esther M John; Wendy K Chung; Irene L Andrulis; Melissa Southey; Mary B Daly; Saundra S Buys; Ana Osorio; Christoph Engel; Karin Kast; Rita K Schmutzler; Trinidad Caldes; Anna Jakubowska; Jacques Simard; Michael L Friedlander; Sue-Anne McLachlan; Eva Machackova; Lenka Foretova; Yen Y Tan; Christian F Singer; Edith Olah; Anne-Marie Gerdes; Brita Arver; Håkan Olsson Journal: JAMA Date: 2017-06-20 Impact factor: 56.272
Authors: Kerstin Rhiem; Christoph Engel; Monika Graeser; Silke Zachariae; Karin Kast; Marion Kiechle; Nina Ditsch; Wolfgang Janni; Christoph Mundhenke; Michael Golatta; Dominic Varga; Sabine Preisler-Adams; Tilman Heinrich; Ulrich Bick; Dorothea Gadzicki; Susanne Briest; Alfons Meindl; Rita K Schmutzler Journal: Breast Cancer Res Date: 2012-12-07 Impact factor: 6.466
Authors: Philipp Harter; Jan Hauke; Florian Heitz; Alexander Reuss; Stefan Kommoss; Frederik Marmé; André Heimbach; Katharina Prieske; Lisa Richters; Alexander Burges; Guido Neidhardt; Nikolaus de Gregorio; Ahmed El-Balat; Felix Hilpert; Werner Meier; Rainer Kimmig; Karin Kast; Jalid Sehouli; Klaus Baumann; Christian Jackisch; Tjoung-Won Park-Simon; Lars Hanker; Sandra Kröber; Jacobus Pfisterer; Heidrun Gevensleben; Andreas Schnelzer; Dimo Dietrich; Tanja Neunhöffer; Mathias Krockenberger; Sara Y Brucker; Peter Nürnberg; Holger Thiele; Janine Altmüller; Josefin Lamla; Gabriele Elser; Andreas du Bois; Eric Hahnen; Rita Schmutzler Journal: PLoS One Date: 2017-10-20 Impact factor: 3.240